Britta Kehden

Statistics

Publications

Citations

153

H-Index

Active since

2016

Affiliations

University Hospital Schleswig-Holstein(Current)

University of Lübeck

Ludwig-Maximilians-Universität München

Roche (Switzerland)

Roche (United Kingdom)

Britta Kehden is an author at University Hospital Schleswig-Holstein specializing in minimal residual disease markers, minimal residual disease, and residual disease in lymphoma.

Publications per year

2016–2023

Publications

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study

Christiane Pott, Eva Hoster, Britta Kehden et al. · Blood · 2016 · 46 citations

Medicine, Hematology, Oncology +14

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

Christiane Pott, Laurie H. Sehn, David Belada et al. · Leukemia · 2019 · 33 citations · Full text

Medicine, Immunology, Oncology +17

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study

Christiane Pott, Vindi Jurinović, Judith Trotman et al. · Journal of Clinical Oncology · 2023 · 32 citations · Full text

Medicine, Hematology, Oncology +10

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Christiane Pott, Eva Hoster, Britta Kehden et al. · Blood · 2018 · 29 citations

Medicine, Hematology, Immunology +12

Somatic <i>TP53</i> mutations are preleukemic events in acute lymphoblastic leukemia

Guranda Chitadze, Anna Stengel, Cathrin John-Klaua et al. · Blood · 2022 · 13 citations · Full text

Medicine, Genetics, Molecular Genetics +11

1–5 of 5